抗素尿素和不耐受性多细胞血症之间的临床结果的差异 维拉患者
Sung-Eun Lee1, Junshik Hong2, Soo-Mee Bang3
1Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Journal of Korean medical science
|January 23, 2024
概括
患有抗氨酸尿素 (HU-R) 的真菌多细胞血症患者患病进展的风险高于不耐受HU (HU-I) 的患者. 然而,血栓形成的风险是相似的,指导未来的治疗决策.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床医学 临床医学
背景情况:
- 多细胞血清病 (PV) 患有氨酸抗性 (HU-R) 或氨酸不耐受 (HU-I) 的患者可能具有不同的特征.
- 之前的研究没有比较这两个群体,也没有评估预后因素.
研究的目的:
- 评估临床结果并确定HU-R或HU-I的PV患者的预后因素.
- 为了比较HU-R和HU-I组之间的疾病进展和血栓发生率.
主要方法:
- 从九个中心对90名患有HU-R或HU-I的PV患者进行了回顾性审查.
- 对临床结果的分析,包括血栓形成和疾病进展.
- 多变量分析以确定生存的预后因素.
主要成果:
- 血栓形成的累积发病率为21.4%,疾病进展率为22.5%,长达7年.
- 与HU-I患者 (0.56%) 相比,HU-R患者的疾病进展率明显高 (36.7%).
- HU-R是无进展生存的独立预后因素 (HR,6.27). 较高的LDH,心血管风险因素和先前的血栓形成预测了整体存活率.
结论:
- 患有HU-R的PV患者面临更高的血液转变风险,但血栓形成的风险与HU-I患者相似.
- 这些发现突出了关键的区别,应该为二线治疗选择和临床试验设计提供信息.
更多相关视频
相关概念视频
Disorders of Erythrocytes
940
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
940
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
216
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
216
Vascular Resistance
4.0K
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
4.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158


